Spots Global Cancer Trial Database for A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)
Official Title: A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer
Study ID: NCT04871997
Conditions
Interventions
Study Description
Brief Summary: A real-world study: Efficacy and safety of Anlotinib for advanced non-small cell lung cancer：This study aims to observe and explore the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer in the real world, and to summarize the treatment experience of a broad population.
Detailed Description: A real-world study: Efficacy and safety of Anlotinib for advanced non-small cell lung cancer：This study aims to observe and explore the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer in the real world, and to summarize the treatment experience of a broad population.This study is a non-interventional, prospective, observational, real-world case study and all registered data are collected from real clinical practice cases. Adult patients diagnosed as advanced non-small cell lung cancer and treated with anlotinib were included. At least one tumor lesion has not been subjected to local treatment such as irradiation in the past, and can be accurately measured, the longest diameter is ≥10 mm.The primary endpoint was progression-free survival (PFS) and the secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety.If the last patient reaches the main evaluation index or has intolerable toxic reaction, the observation will be finished, and the first one will prevail.Through Electronic Data Capture System (EDC) system, electronic case report form (eCRF) is used to replace paper-based case report form to collect and manage clinical trial data.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hubei province, Wuhan, Hubei, China
Contact Details
Name: Qian Chu
Affiliation: Tongji Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Tienan Yi
Affiliation: Xiangyang Central Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Youhong Dong
Affiliation: Xiangyang No.1 People's Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Ruizhi Ran
Affiliation: The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture
Role: PRINCIPAL_INVESTIGATOR
Name: Yang Fu
Affiliation: Xiangyang Hospital of Traditional Chinese Medicine
Role: PRINCIPAL_INVESTIGATOR
Name: Guangqiao Qu
Affiliation: The Central Hospital of Xiao Gan
Role: PRINCIPAL_INVESTIGATOR
Name: Jun Li
Affiliation: The Central Hospital of Xiao Gan
Role: PRINCIPAL_INVESTIGATOR
Name: Yinping Li
Affiliation: The Central Hospital of Xiao Gan
Role: PRINCIPAL_INVESTIGATOR
Name: Yanhua Xu
Affiliation: Jingzhou Central Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Xinhua Xu
Affiliation: Yichang Central People's Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Zhiguo Luo
Affiliation: Affiliated Taihe Hospital of Hubei University of Medicine
Role: PRINCIPAL_INVESTIGATOR
Name: Fengjun Cao
Affiliation: Shiyan Renmin Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Li Kuang
Affiliation: Dongfeng Hospital Affiliated to Hubei Medical College
Role: PRINCIPAL_INVESTIGATOR
Name: Yifa Yin
Affiliation: The Second People's Hospital of Yichang
Role: PRINCIPAL_INVESTIGATOR
Name: Guiming Chen
Affiliation: JingMen NO.2 People's Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
